[Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer].

The study involved 14 patients with recurrent breast cancer treated with a combination of mitoxantrone, vincristine, and prednisolone (MVP). The treatment showed a 70% objective response rate, with two patients maintaining a response for over 40 weeks. The primary toxicity observed was myelosuppression, with 35.7% of patients experiencing severe leukopenia, which was managed with G-CSF therapy. Nausea and vomiting were well tolerated, and the regimen was noted for maintaining quality of life due to significantly less hair loss compared to CAF treatment. Overall, MVP was found to be highly effective and safe for treating recurrent breast cancer.